<code id='CBFA00AE86'></code><style id='CBFA00AE86'></style>
    • <acronym id='CBFA00AE86'></acronym>
      <center id='CBFA00AE86'><center id='CBFA00AE86'><tfoot id='CBFA00AE86'></tfoot></center><abbr id='CBFA00AE86'><dir id='CBFA00AE86'><tfoot id='CBFA00AE86'></tfoot><noframes id='CBFA00AE86'>

    • <optgroup id='CBFA00AE86'><strike id='CBFA00AE86'><sup id='CBFA00AE86'></sup></strike><code id='CBFA00AE86'></code></optgroup>
        1. <b id='CBFA00AE86'><label id='CBFA00AE86'><select id='CBFA00AE86'><dt id='CBFA00AE86'><span id='CBFA00AE86'></span></dt></select></label></b><u id='CBFA00AE86'></u>
          <i id='CBFA00AE86'><strike id='CBFA00AE86'><tt id='CBFA00AE86'><pre id='CBFA00AE86'></pre></tt></strike></i>

          entertainment

          entertainment

          author:knowledge    Page View:1976

          The Senate has set its eyes on regulating insurance plans for some of the most vulnerable patients in the U.S. — the 12.5 million people eligible for both Medicare and Medicaid.

          “They’re a complex group of people with a lot of chronic conditions — mental illness, frailty, disability,” said Jose Figueroa, an internal medicine physician and health policy expert at Brigham and Women’s Hospital. Over a third of these dual-eligible beneficiaries have less than a high school education, and about 90% make less than $20,000 per year.

          advertisement

          Just around 15% of beneficiaries are eligible for both Medicare and Medicaid, but they account for a third of these programs’ spending — around $440 billion — and still don’t receive better health care, Sen. Bill Cassidy (R-La.) pointed out in a JAMA viewpoint published earlier this month. “The root cause of worse outcomes despite spending more money is a lack of coordination of care,” Cassidy wrote.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Is mRNA technology the right fit for flu shots? Experts aren’t so sure
          Is mRNA technology the right fit for flu shots? Experts aren’t so sure

          MollyFergusonforSTATHerearetwothingsthataretrue.Theworldneedsmoreeffectivefluvaccines.Andpharmaceuti

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          How faith leaders like me can help address America's obesity epidemic

          AdobeManyfactorsdriveAmerica’sobesityepidemic—environment,genetics,eatinghabits,andmore.Solvingthepr